Home
Live Updates
TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC : comparemela.com
TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC
Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.
Related Keywords
Italy ,
Riccardo Lencioni ,
Department Of Surgery ,
Cancers Symposium ,
Critical Area Pathology ,
D ,
Chemoembolization Tace ,
Urvalumab Imfinzi ,
Nd Bevacizumab Avastin ,
Hepatocellular Carcinoma ,
Hcc ,
Phase 3 Emerald 1 Trial Nct03778957 ,
comparemela.com © 2020. All Rights Reserved.